title: Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.
abstract: BACKGROUND
  Traditionally inhaled treatment for asthma has used separate preventer and reliever therapies. The combination of formoterol and budesonide in one inhaler has made possible a single inhaler for both prevention and relief of symptoms (single inhaler therapy or SiT).
  
  
  OBJECTIVE
  To assess the efficacy and safety of budesonide and formoterol in a single inhaler for maintenance and reliever therapy in asthma compared with maintenance with inhaled corticosteroids (ICS) (alone or as part of current best practice) and any reliever therapy.
  
  
  METHODS
  We searched the Cochrane Airways Group trials register in February 2013.
  
  
  METHODS
  Parallel, randomised controlled trials of 12 weeks or longer in adults and children with chronic asthma. Studies had to assess the combination of formoterol and budesonide as SiT, against a control group that received inhaled steroids and a separate reliever inhaler.
  
  
  METHODS
  We used standard methodological procedures expected by The Cochrane Collaboration.
  
  
  RESULTS
  We included 13 trials involving 13,152 adults and one of the trials also involved 224 children (which have been separately reported). All studies were sponsored by the manufacturer of the SiT inhaler. We considered the nine studies assessing SiT against best practice to be at a low risk of selection bias, but a high risk of detection bias as they were unblinded.In adults whose asthma was not well-controlled on ICS, the reduction in hospital admission with SiT did not reach statistical significance (Peto odds ratio (OR) 0.81; 95% confidence interval (CI) 0.45 to 1.44, eight trials, N = 8841, low quality evidence due to risk of detection bias in open studies and imprecision). The rates of hospital admission were low; for every 1000 people treated with current best practice six would experience a hospital admission over six months compared with between three and eight treated with SiT. The odds of experiencing exacerbations needing treatment with oral steroids were lower with SiT compared with control (OR 0.83; 95% CI 0.70 to 0.98, eight trials, N = 8841, moderate quality evidence due to risk of detection bias). For every 100 adults treated with current best practice over six months, seven required a course of oral steroids, whilst for SiT there would be six (95% CI 5 to 7). The small reduction in time to first severe exacerbation needing medical intervention was not statistically significant (hazard ratio (HR) 0.94; 95% CI 0.85 to 1.04, five trials, N = 7355). Most trials demonstrated a reduction in the mean total daily dose of ICS with SiT (mean reduction was based on self-reported data from patient diaries and ranged from 107 to 385 µg/day). Withdrawals due to adverse events were more common in people treated with SiT (OR 2.85; 95% CI 1.89 to 4.30, moderate quality evidence due to risk of detection bias).Three studies including 4209 adults compared SiT with higher dose budesonide maintenance and terbutaline for symptom relief. The studies were considered as low risk of bias. The run-in for these studies involved withdrawal of LABA, and patients were recruited who were symptomatic during run-in. The reduction in the odds of hospitalisation with SiT compared with higher dose ICS did not reach statistical significance (Peto OR; 0.56; 95% CI 0.28 to 1.09, moderate quality evidence due to imprecision). Fewer patients on SiT needed a course of oral corticosteroids (OR 0.54; 95% CI 0.45 to 0.64, high quality evidence). For every 100 adults treated with ICS over 11 months, 18 required a course of oral steroids, whilst for SiT there would be 11 (95% CI 9 to 12). Withdrawals due to adverse events were more common in people treated with SiT (OR 0.57; 95% CI 0.35 to 0.93, high quality evidence).One study included children (N = 224), in which SiT was compared with higher dose budesonide. There was a significant reduction in participants who needed an increase in their inhaled steroids with SiT, but there were only two hospitalisations for asthma and no separate data on courses of oral corticosteroids. Less inhaled and oral corticosteroids were used in the SiT group and the annual height gain was also 1 cm greater in the SiT group, (95% CI 0.3 cm to 1.7 cm).The results for fatal serious adverse events were too rare to rule out either treatment being harmful. There was no significant difference found in non-fatal serious adverse events for any of the comparisons.
  
  
  CONCLUSIONS
  Single inhaler therapy has now been demonstrated to reduce exacerbations requiring oral corticosteroids against current best practice strategies and against a fixed higher dose of inhaled steroids. The strength of evidence that SiT reduces hospitalisation against these same treatments is weak. There were more discontinuations due to adverse events on SiT compared to current best practice, but no significant differences in serious adverse events. Our confidence in these conclusions is limited by the open-label design of the trials, and by the unknown adherence to treatment in the current best practice arms of the trials.Single inhaler therapy can reduce the risk of asthma exacerbations needing oral corticosteroids in comparison with fixed dose maintenance ICS and separate relief medication. The reduced odds of exacerbations with SiT compared with higher dose ICS should be viewed in the context of the possible impact of LABA withdrawal during study run-in. This may have made the study populations more likely to respond to SiT.Single inhaler therapy is not currently licensed for children under 18 years of age in the United Kingdom and there is currently very little research evidence for this approach in children or adolescents.
authors: Population Health Sciences and Education, St George’s, University of London, London, UK. ccates@sgul.ac.uk.
authors: Christopher J
authors: CJ
authors: Cates
authors: Charlotta
authors: C
authors: Karner
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage; D019819:Budesonide / Q000008:administration & dosage*; D002648:Child; D002908:Chronic Disease; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage*; D000068759:Formoterol Fumarate; D006801:Humans; D013726:Terbutaline / Q000008:administration & dosage
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D004338:Drug Combinations; D004983:Ethanolamines; D019819:Budesonide; D013726:Terbutaline; D000068759:Formoterol Fumarate
references: Pulm Pharmacol Ther. 2001;14(1):29-34
references: 11162416
references: J Asthma. 2011 Oct;48(8):839-47
references: 21942354
references: Eur Respir J. 2006 Oct;28(4):748-55
references: 17012630
references: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006923
references: 22513944
references: Am J Respir Crit Care Med. 2005 Jan 15;171(2):129-36
references: 15502112
references: Lancet. 2004 Jan 24;363(9405):271-5
references: 14751699
references: Chest. 2006 Dec;130(6):1733-43
references: 17166990
references: Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006924
references: 19370661
references: Prim Care Respir J. 2012 Mar;21(1):50-6
references: 22015542
references: Evid Based Nurs. 2005 Jul;8(3):78
references: 16021707
references: Pharmacoeconomics. 2006;24(7):695-708
references: 16802845
references: Respir Med. 2007 Mar;101(3):467-75
references: 16949264
references: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006922
references: 19588410
references: J Allergy Clin Immunol. 2007 Jun;119(6):1332-6
references: 17451803
references: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD005535
references: 16235410
references: Clin Ther. 2008 Mar;30(3):560-71
references: 18405796
references: Am J Respir Crit Care Med. 1999 Aug;160(2):594-9
references: 10430734
references: Eur Respir J. 2005 Nov;26(5):819-28
references: 16264042
references: Lancet. 2001 Jan 27;357(9252):257-61
references: 11214127
references: Cochrane Database Syst Rev. 2010 Apr 14;(4):CD005533
references: 20393943
references: Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004106
references: 18646100
references: Eur Respir J. 2008 May;31(5):982-9
references: 18216054
references: Respir Med. 2007 Dec;101(12):2437-46
references: 17905575
references: Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007694
references: 20091646
references: Eur Respir J. 2002 Oct;20(4):859-66
references: 12412676
references: Cochrane Database Syst Rev. 2011 May 11;(5):CD003137
references: 21563136
references: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003135
references: 16235315
references: Cochrane Database Syst Rev. 2012 Mar 14;(3):CD007695
references: 22419326
references: Thorax. 2004 Jul;59(7):550-6
references: 15223858
references: Respir Res. 2006 Dec 04;7:141
references: 17144916
references: Curr Med Res Opin. 2007 Aug;23(8):1867-78
references: 17605896
references: BMJ. 2007 Sep 8;335(7618):513
references: 17823193
references: Eur Respir J. 2010 Sep;36(3):524-30
references: 20595145
references: Curr Med Res Opin. 2004 Sep;20(9):1403-18
references: 15383189
references: Pediatr Pulmonol. 2003 Nov;36(5):391-8
references: 14520721
references: Respir Med. 2001 Sep;95(9):753-8
references: 11575897
references: Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007313
references: 19370682
references: Br J Gen Pract. 2008 Jan;58(546):37-43
references: 18186995
references: Respir Med. 2009 Nov;103(11):1623-32
references: 19762222
references: Lancet. 2006 Aug 26;368(9537):744-53
references: 16935685
references: Chest. 2006 Feb;129(2):246-256
references: 16478838
references: Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006363
references: 18646149
references: Curr Med Res Opin. 2006 May;22(5):809-21
references: 16709303
references: Int J Clin Pract. 2007 May;61(5):725-36
references: 17362472
references: Allergy. 2007 Oct;62(10):1189-98
references: 17845590
references: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001385
references: 17253458
references: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD007949
references: 19588447
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120